ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone marrow metastasis is rare in lung adenocarcinoma, and has been reported to be associated with poor prognosis. Here, we report the case of a 62‐year‐old female diagnosed with lung adenocarcinoma and bone marrow metastasis. ERBB2 exon 20 insertion mutation was confirmed by next‐generation sequencing (NGS) of lung tissue as well as bone marrow. The patient achieved stable disease and recovery of pancytopenia after two months of pyrotinib therapy. This is the first report of homogenous mutations of ERBB2 detected in bone marrow, as well as a good response of bone marrow to pyrotinib therapy.

中文翻译：

---

非小细胞肺癌和ERBB2突变患者成功治疗吡咯替尼引起的骨髓转移引起的全血细胞减少症。

约2％的非小细胞肺癌（NSCLC）患者发现ERBB2突变。最近的一项研究报道，对于具有ERBB2突变的患者，吡咯替尼（一种不可逆的pan ErbB抑制剂）比其他酪氨酸激酶抑制剂疗法具有更好的抗肿瘤作用。骨髓转移在肺腺癌中很少见，据报道与不良预后有关。在这里，我们报告一例62岁的女性，被诊断患有肺腺癌和骨髓转移。ERBB2通过肺组织和骨髓的下一代测序（NGS）证实了第20外显子插入突变。接受焦磷酸替尼治疗两个月后，患者病情稳定，全血细胞减少。这是在骨髓中检测到的ERBB2同源突变的首次报道，也是骨髓对吡咯替尼疗法的良好反应。